规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
1mg |
|
||
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
SNX-2112 是一种口服活性 Hsp90 抑制剂,Her-2 降解的 IC50 为 10 nM,Kd 为 16 nM[3]。 SNX-2112 与 Hsp90 结合; Hsp90 α 和 β、Grp94 和 Trap-1 的 IC50 值分别为 30 nM、30 nM、4.275 μM 和 0.862 μM [1]。 SNX-2112 的 IC50 值范围为 3 nM 至 53 nM,表明对多种类型的癌细胞具有强大的抗增殖作用。 SNX-2112 的 IC50 值分别为 11 ± 5、41 ± 12 和 1 ± 0.6 nM,对 AU565 细胞中的 Her2 和 p-ERK 稳定性以及 A375 细胞中的 p-S6 表现出强烈影响。 SNX-2112 的 IC50 为 2 ± 0.9 nM,还可激活 A375 细胞中的 Hsp70[3]。此外,SNX-2112 可以在许多细胞类型中有效阻断 Hsp90 客户端信号传导,包括 Akt、ERK 和 NF-κB 通路。 SNX-2112 48 小时的 IC50 值为 52、55、19、186、89、67、93 和 53 nM,可抑制多发性骨髓瘤 (MM) 细胞系的增殖,包括 MM.1S、U266、INA-6 、RPMI8226、OPM1、OPM2、MM.1R 和 Dox40 MM 细胞系。除了下调 ERK/c-fos 和 PU.1 之外,SNX-2112 (2.5–10 nM) 还可以阻止破骨细胞的发育 [4]。
|
||
---|---|---|---|
体内研究 (In Vivo) |
SNX-2112 由其前药 SNX-5422 递送,在异种移植小鼠模型中抑制 MM 细胞生长并延长存活时间,SNX-2112 对 Hsp90 的阻断不仅抑制 MM 细胞生长,而且还在骨髓微环境中发挥作用,阻断血管生成和破骨细胞生成。
|
||
动物实验 |
|
||
参考文献 |
[1]. Chandarlapaty S, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 2008 Jan 1;14(1):240-8.
[2]. Mishra SJ, et al. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold. ACS Chem Biol. 2017 Jan 20;12(1):244-253. [3]. Huang KH, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem. 2009 Jul 23;52(14):4288-305 [4]. Okawa Y, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 2009 Jan 22;113(4):846-55 |
分子式 |
C23H27F3N4O3
|
|
---|---|---|
分子量 |
464.48
|
|
CAS号 |
908112-43-6
|
|
相关CAS号 |
|
|
SMILES |
O=C(N)C1=CC=C(N2N=C(C(F)(F)F)C3=C2CC(C)(C)CC3=O)C=C1N[C@H]4CC[C@H](O)CC4
|
|
InChi Key |
ZFVRYNYOPQZKDG-MQMHXKEQSA-N
|
|
InChi Code |
InChI=1S/C23H27F3N4O3/c1-22(2)10-17-19(18(32)11-22)20(23(24,25)26)29-30(17)13-5-8-15(21(27)33)16(9-13)28-12-3-6-14(31)7-4-12/h5,8-9,12,14,28,31H,3-4,6-7,10-11H2,1-2H3,(H2,27,33)/t12-,14-
|
|
化学名 |
4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-(((1r,4r)-4-hydroxycyclohexyl)amino)benzamide
|
|
别名 |
PF 04928473; SNX2112; SNX-2112;PF-04928473; PF04928473; SNX 2112
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 0.5% CMC+0.25% Tween 80: 30mg/mL 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1529 mL | 10.7647 mL | 21.5295 mL | |
5 mM | 0.4306 mL | 2.1529 mL | 4.3059 mL | |
10 mM | 0.2153 mL | 1.0765 mL | 2.1529 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02612285 | Terminated Has Results | Drug: SNX-5422 | Cancer | Esanex Inc. | March 2016 | Phase 2 |
NCT02914327 | Withdrawn | Drug: SNX-5422 plus ibrutinib | Cancer | Esanex Inc. | February 2, 2017 | Phase 1 |
NCT02973399 | Terminated | Drug: SNX-5422 plus ibrutinib | Cancer | Esanex Inc. | February 7, 2017 | Phase 1 |
SNX-2112 and 17-AAG induce Hsp90 client degradation, inhibit Erk and Akt activation, and induce apoptosis in HER2-overexpressing cells. A, kinetics of client protein degradation in BT-474 cells treated with 1 μmol/L SNX-2112 and 17-AAG showing that both drugs induce client protein degradation with similar kinetics. Immunoblots were done using 25 to 50 μg of cell lysate. B, SNX-2112 and 17-AAG degraded Hsp90 clients with similar potency. Cells were treated with SNX-2112 or 17-AAG for 24 h followed by collection and analysis. td> |
Effect of 17-AAG and SNX-2112 on growth and cell cycle in multiple cell lines. A, indicated cell lines were seeded in 96-well plates and treated with increasing concentrations of 17-AAG or SNX-2112. The mean number of viable cells is reported as the percentage of the untreated count subtracting day 0 along with SD. Curves are representative of three independent experiments. B, BT-474 and MDA-468 cells were treated with the indicated concentrations of 17-AAG or SNX-2112 in triplicate and collected after 48 h. Nuclei were isolated, stained with ethidium bromide, and analyzed for DNA content and thus cell cycle distribution by flow cytometry. Apoptosis is reported as a mean of the sub-G1 fraction. td> |
Effect of a single, nontoxic dose of SNX-5542 in vivo. BT474 tumor-bearing mice were sacrificed and tumors were collected at the indicated times after treatment by oral gavage with a single dose of 50 mg/kg SNX-5542. Immunoblotting was done on tumor lysates using the indicated antibodies. Comparable data were obtained with several other doses including 75, 100, and 150 mg/kg (data not shown). td> |